ARS Pharmaceuticals (SPRY) Profit After Tax (2020 - 2026)

ARS Pharmaceuticals has reported Profit After Tax for 7 years, with the latest figure at -$60.6 million in Q1 2026.

• Quarterly Profit After Tax fell 78.6% year-over-year to -$60.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$198.1 million (down 1219.59% YoY) and the FY2025 annual result came in at -$171.4 million, down 2198.09% from the prior year.
• Profit After Tax retreated to -$60.6 million in Q1 2026 per SPRY's latest filing, from -$41.4 million in the prior quarter.
• Over five years, Profit After Tax peaked at $50.1 million in Q4 2024 and troughed at -$60.6 million in Q1 2026.
• A 5-year average of -$18.4 million and a median of -$14.9 million in 2023 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2024 and 2025: Profit After Tax jumped 799.01% in 2024, then sank 258.95% in 2025.
• Over 5 years, Profit After Tax stood at -$14.4 million in 2022, then surged by 50.32% to -$7.2 million in 2023, then surged by 799.01% to $50.1 million in 2024, then tumbled by 182.66% to -$41.4 million in 2025, then plunged by 46.35% to -$60.6 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$60.6 million, -$41.4 million, and -$51.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.